Fenwick represented KaliVir Immunotherapeutics, a biotechnology company developing oncolytic viral immunotherapy programs, in its strategic collaboration and global exclusive licensing agreement with Roche, a provider of in-vitro diagnostics and supplier of innovative solutions across major disease areas. KaliVir will work with Roche to leverage KaliVir's proprietary technology platform based on genetically modified vaccinia virus to discover and develop novel oncolytic virus candidates.
Under the terms of the agreement, KaliVir will generate oncolytic vaccinia virus product candidates derived from the company's VET platform expressing Roche proprietary therapeutic transgenes. Roche will have exclusive license to discover, develop and commercialize the products worldwide. KaliVir will receive an upfront payment, and may be eligible to receive research, development and commercial milestone payments, as well as tiered royalties on commercial sales of products emerging from the collaboration. More information about the collaboration can be obtained from the announcement.
The Fenwick transaction team included life science partner Jake Handy and tax partner William Skinner.